HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD Could Jog Cognitive Benefit Supplement Firm's Memory With FTC Call

This article was originally published in The Rose Sheet

Executive Summary

NAD refers UltraMax Health's supplement claim to the FTC after it fails to provide substantiation. CRN emphasizes claims alone are not the problem, but the firm's failure to provide substantiation.

You may also be interested in...



Memory Health Marketer Reminded About Brain Health Ad Claims Substantiation In NAD Review

Michigan firm likely remembered burden for substantiating health as well as structure/function claims under FDA regulations for supplements after NAD reviewed its ad materials presented online, in videos and in news releases submitted by Vision Elements.

Avantius Launches Supplement After Study Finds Formulation Slowed Alzheimer’s Progression

Memory Health supplement was developed and is launching in the US after a small European study of Alzheimer’s patients finds improvement in patients taking a carotenoid/omega-3 combination, says marketer Avantius Group. A larger-scale, double blinded clinical study is underway in Europe.

'Enhanced Brain Function' Supplement Sales Only A Memory After NAD Review

Council of Better Business Bureau's industry self-regulation arm says UltraMax Health, after previously not responding to a request for evidence supporting Max Synapse online ad claims, stated in writing that it stopped using the claims and no longer is selling the product.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel